Mermisi Llc Pharmaceutical Import Profile — Georgia (DGFT 2022–2026)

Name: Mermisi Llc Pharmaceutical Import Records from India — 5 Products, $2.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mermisi Llc — Pharmaceutical Importer Profile (2026) | 5 Products, $2.3M Trade | TransData Nexus

Mermisi Llc

Pharmaceutical Importer · Georgia · Oncology Focus · $2.3M Total Trade · DGFT Verified

Mermisi Llc is a pharmaceutical importer based in Georgia with a total trade value of $2.3M across 5 products in 3 therapeutic categories. Based on 63 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mermisi Llc sources from 6 verified Indian suppliers, with Getwell Pharma India Private Limited accounting for 66.1% of imports.

Mermisi Llc — Import Portfolio & Supplier Network

Mermisi Llc import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mermisi Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Getwell Pharma India Private Limited	$1.2M	55	66.1%
Getwell Pharmaceuticals	$394.6K	20	22.0%
G P Interglobe	$126.0K

What Formulations Does Mermisi Llc Import?

Formulation	Value	Ships
Alpaxel 100MG (paclitaxel (protein	$517.0K	12
Targe-dox 20MG/10ML (doxorubicin hcl	$117.5K	4
Alpaxel 100MG (paclitaxel(protein boundparticles)for injectable suspension)b.no.4gpnl03, mfg.dt. 04/2024,exp	$50.0K	1
Alpaxel 100MG(paclitaxel(protein bound particles)for injectable suspension)batchno.4gpnl04mfg.dt.05/2024	$50.0K	1
Alpaxel 100MG(paclitaxel(protein bound particles)for injectable suspension)batchno.4gpnl05	$50.0K	1
Alpaxel 100MG(paclitaxel (protein boundparticles) for injectable suspension)batch- 5gpnl01, mfg.dt. 01/25,exp.dt.	$50.0K	1
Alpaxel 100MG(paclitaxel (protein boundparticles) for injectable suspension)batch-5gpnl02, mfg.dt. 01/25,exp.dt.	$50.0K	1
Alpaxel 100MG(paclitaxel(protein bound particles)for injectable suspension)batchno.5gpnl04,mfg.dt.02/2025	$50.0K	1
Alpaxel 100MG (paclitaxel (protein bound particles) for injectable suspension) b.: 5gpnl05 m.: 02/2025 e.	$50.0K	1
Alpaxel 100MG (paclitaxel (protein bound particles) for injectable suspension) b.: 5gpnl06 m.: 03/2025 e.	$50.0K	1
Alpaxel 100MG paclitaxel protein bound particles for injectable suspension batch 5gpnl09 mfg dt 05 2025 exp dt 04	$50.0K	1
Taxewell rtu-20MG/ML (docetaxel	$48.6K	2
Targe-dox 20MG/10ML (doxorubicin hydrochloride liposome injection) batch no. 5gid02, mfg.dt. 01/2025, exp.dt.	$46.3K	1
Targe-dox 20MG/10ML (doxorubicin hcl liposome INJ.),batch no. 4gid06, mfg.dt. 04/2024, exp.dt.	$41.5K	1
Gemcit 1g (gemcitabine for injection	$40.6K	4

Mermisi Llc imports 88 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paclitaxel	Oncology	$1.1M	23	1.4%	6
2	Protein	Nutritional Supplements	$1.1M	21	7.1%	2
3	Pembrolizumab	Advanced Oncology	$59.9K	6	3.1%	3
4	Daratumumab	Advanced Oncology	$54.0K	8	4.0%	6
5	Pazopanib	Advanced Oncology	$27.1K	5	0.3%	9

Mermisi Llc imports 5 pharmaceutical products across 3 categories into Georgia totaling $2.3M.

Mermisi Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mermisi LLC, established in 1993, is a privately held pharmaceutical company headquartered in Tbilisi, Georgia. Specializing in the registration, import, and distribution of pharmaceutical products, Mermisi has been a leader in the Georgian pharmaceutical sector for over three decades. The company focuses on introducing innovative medical products, including targeted anticancer medicines, biosimilars, and advanced biologic and nanotechnologically advanced drugs, thereby contributing significantly to public health and welfare in Georgia. (mermisi.ge)

With a team of 11-50 employees, Mermisi LLC has developed strong partnerships with global pharmaceutical manufacturers, facilitating the launch and scaling of oncology products in Georgia. Their comprehensive services encompass regulatory approval, reimbursement, distribution, promotion, and long-term market growth, positioning them as a preferred partner for market entry and commercial success in Georgia's specialty pharmaceutical sector. (mermisi.ge)

2Distribution Network

Mermisi LLC operates a centralized distribution network from its headquarters in Tbilisi, Georgia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive experience and partnerships suggest a well-established infrastructure capable of efficiently managing the import and distribution of pharmaceutical products across Georgia. Their focus on oncology and specialty pharmaceuticals indicates a strategic approach to logistics, ensuring timely and reliable delivery to healthcare providers nationwide.

3Industry Role

In Georgia's pharmaceutical supply chain, Mermisi LLC functions primarily as a pharmaceutical importer and distributor. The company plays a pivotal role in introducing and supplying innovative medical products, particularly in the oncology and specialty sectors, to the Georgian market. By partnering with global manufacturers, Mermisi ensures the availability of advanced therapies, thereby enhancing the quality of healthcare services in the country. (mermisi.ge)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mermisi Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mermisi LLC's sourcing strategy reveals a significant concentration on a select group of suppliers. The company's total import value from India amounts to $2.3 million USD, with 63 shipments covering five products across three therapeutic categories. The top five products imported include Paclitaxel and Protein, each valued at $1.1 million USD, accounting for 1.4% and 7.1% of the total share, respectively. This concentration indicates a strategic choice to focus on high-value, specialized products, potentially leveraging supplier expertise and favorable pricing.

The shipment data, with 55 shipments from GETWELL PHARMA INDIA PRIVATE LIMITED and 20 from GETWELL PHARMACEUTICALS, suggests a stable and ongoing relationship with these suppliers. However, the reliance on a limited number of suppliers may pose risks related to supply chain disruptions or changes in supplier dynamics. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

Mermisi LLC's supply chain resilience appears robust, given the company's longstanding partnerships with key Indian suppliers. The diversity in imported formulations, with 88 unique products, indicates a broad sourcing strategy within the oncology and specialty pharmaceutical sectors. While the primary suppliers are GETWELL PHARMA INDIA PRIVATE LIMITED and GETWELL PHARMACEUTICALS, the presence of additional suppliers like G P INTERGLOBE and THERDOSE PHARMA PRIVATE LIMITED suggests a level of diversification.

Importing Pharmaceuticals into Georgia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Georgia

1Regulatory Authority & Framework

In Georgia, the regulation of pharmaceutical products is overseen by the Agency of State Regulation of Medical Activities at the Ministry of Labor, Health and Social Protection. This agency is responsible for the registration, import, and distribution of pharmaceutical products, ensuring compliance with national and international standards. The legal framework governing pharmaceutical activities includes the Law of Georgia on Medicines and Pharmaceutical Activities, which outlines the procedures for drug registration, importation, and distribution. (matsne.gov.ge)

The registration process for pharmaceutical products in Georgia can be conducted through two regimes: national and recognition. The recognition regime allows for the simplified registration of drugs already approved by stringent regulatory authorities, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA), without the need for re-testing. This facilitates faster market entry for products that have already undergone rigorous evaluation. (mkdlaw.ge)

2Import Licensing & GMP

Importing pharmaceutical products into Georgia requires obtaining a specific permit from the Regulation Agency. Additionally, warehouses must meet Good Distribution Practice (GDP) standards to ensure the quality and integrity of the products during storage and transportation. Compliance with GDP is mandatory for pharmaceutical distributors in Georgia, as it ensures that medicines are consistently stored, transported, and handled under suitable conditions. (legal.ge)

Mermisi Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mermisi LLC's product strategy focuses on high-value, specialized pharmaceutical products, particularly in the oncology and specialty sectors. The company's top five imported products—Paclitaxel, Protein, Pembrolizumab, Daratumumab, and Pazopanib—align with this focus, addressing critical therapeutic areas with significant market demand. This strategic emphasis allows Mermisi to meet the needs of patients requiring advanced therapies and positions the company as a leader in providing innovative treatments in Georgia. (mermisi.ge)

The market demand for these products is driven by the increasing prevalence of cancer and other complex diseases in Georgia, necessitating access to cutting-edge treatments. By importing these specialized products, Mermisi LLC contributes to improving patient outcomes and advancing the standard of care in the country.

2Sourcing Profile

Mermisi LLC's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic drugs and specialized formulations. The company's preference for finished products allows for quicker market entry and ensures that the imported medicines are ready for distribution without the need for additional processing. India's robust pharmaceutical manufacturing sector, known for its compliance with international quality standards, makes it a strategic sourcing partner for Mermisi.

Frequently Asked Questions — Mermisi Llc

What products does Mermisi Llc import from India?

Mermisi Llc imports 5 pharmaceutical products across 3 categories. Top imports: Paclitaxel ($1.1M), Protein ($1.1M), Pembrolizumab ($59.9K), Daratumumab ($54.0K), Pazopanib ($27.1K).

Who supplies pharmaceuticals to Mermisi Llc from India?

Mermisi Llc sources from 6 verified Indian suppliers. The primary supplier is Getwell Pharma India Private Limited (66.1% of imports, $1.2M).

What is Mermisi Llc's total pharmaceutical import value?

Mermisi Llc's total pharmaceutical import value from India is $2.3M, based on 63 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mermisi Llc focus on?

Mermisi Llc imports across 3 categories. The largest: Oncology (49.1%), Nutritional Supplements (44.9%), Advanced Oncology (6.0%).

Get Full Mermisi Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.